KENDELL HITT: Open Payments
NPI 1609541796 · SCHENECTADY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$586 in 24 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $461 · 2025 $586
Food & beverage: $586
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 11 | $265 |
| Lilly USA, LLC | 3 | $68 |
| Grifols USA, LLC | 2 | $59 |
| Actelion Pharmaceuticals US, Inc. | 2 | $55 |
| AstraZeneca Pharmaceuticals LP | 2 | $48 |
| HARMONY BIOSCIENCES LLC | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| JAZZ PHARMACEUTICALS INC. | 1 | $22 |
Products named: NUCALA, ZEPBOUND, Prolastin-C Liquid, WAKIX, TRELEGY ELLIPTA, OPSUMIT, BREZTRI, GLASSIA.
Industry payments across NY — which companies pay providers there.
